ArticleScientific reports2022

The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis.

Tzu-Hsuan Chiu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.